Fixed price, unfixed volume: the company is locked into a rate while the amount it can sell against it is climbing
The model's full reasoning — Q1 2023 call → NOWe need to determine if management describes a situation where the price/rate/fee is already fixed or contractually set, and the quantity of business at that rate is currently rising or about to rise, with the reported results reflecting lower volume. Let's analyze the transcript. Key points: - Manufacturing facility: "We have a manufacturing facility that is at capacity for which we have enormous demand." "We have brands, some of the largest brands in the world are coming to us and want us to do their manufacturing, some of them want us to do all of their manufacturing, not only in the United States but globally." "So the potential for a manufactured facility is extraordinary." "I've mentioned in the past that I think we have demand for at least $25 million of revenues next year in 2024, and we're just constrained by how quickly we can build out the additional capacity, which is going to take this year to do so. So right now, our revenues are running up almost a 100% year over year." This suggests that the manufacturing business has demand, and they are expanding capacity. But is the price/rate fixed? They talk about manufacturing for brands, likely under contracts with set prices. However, the transcript doesn't explicitly say the rate is fixed. It says "demand" and "revenues running up almost 100% year over year." But the question is about a situation where the rate is already settled and volume is rising. The manufacturing facility is at capacity, so volume is constrained, but they are building out additional capacity. The rate side? They don't explicitly say the price per unit is fixed. They talk about demand and revenue growth. But the essence is that they have contracts? Not explicitly. - Nebula Genomics: "We are waiting for the validations, which will take another couple of months and then we will start to build out those businesses in the second half of this year with our whole genome sequencing business." "We cannot aggressively build a B2B business until we are processing these specimens in-house." "So we anticipate building a very nice Nebula Genomics business the second half of this year, particularly in the fourth quarter." "In the meantime, our revenues are running up more than 100% year over year anyway." This is about volume growth, but the rate? They sell whole genome sequencing tests to consumers and B2B.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
ABR · Q4 2016 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing the Agency Business servicing portfolio at $13.6 billion with a fixed 48 basis point weighted average servicing fee that is already contracted and recurring. They explicitly note the portfolio is growing through recent originations, including $700 million closed in December, which will drive higher servicing income in Q 1. Management states they expect the portfolio to generate over $65 million annually and references growth from 2015 levels, indicating the reported Q4 results reflect a lower average volume during the quarter while the settled economics now scale with the increasing volume arriving in Q1.
FIX · Q1 2017 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing a situation where pricing is stable and contracts (backlog) lock in rates, while volume is rising through backlog growth and upcoming organic work. The Q1 results reflect lower seasonal volume, with the backlog supporting higher throughput ahead. This fits the criteria of settled rates on meaningful contracted business with 13% backlog increase driving volume step-up.
CHE · Q3 2022 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES Management describes Medicare reimbursement rates as already fixed by regulation (CMS), with the volume side now rising through a first significant expansion of clinical staff and patient capacity since the pandemic, plus strengthening admissions and weekly ADC growth in the second half. The reported quarter reflects lower volume (ADC down 4.